TScan Therapeutics Q3 revenue jumps

Reuters

Nov 12, 2025

TScan <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 revenue jumps

Overview

TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements
Net loss for Q3 2025 increased due to higher R&D expenses
Company reached FDA agreement on pivotal trial design for TSC-101

Outlook

Company expects cash reserves to fund operations into the second half of 2027
Enrollment in solid tumor trial paused to focus on preclinical development

Result Drivers

R&D EXPENSES: Research and development (R&D) expenses for the third quarter of 2025 were $31.7 million, compared to $26.3 million for the third quarter of 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Collaboration and License Revenue		$2.51 mln
Q3 Net Income		-$35.71 mln
Q3 Basic EPS		-$0.28
Q3 Income From Operations		-$37.05 mln
Q3 Operating Expenses		$39.56 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 79.7% above its November 11 closing price of $1.22

Press Release: ID:nGNX9WGD6S

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582375632"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582375632\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582375632?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582375632","market":"fut","top_or_hot":-1,"title":"TScan Therapeutics Q3 revenue jumps","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 revenue jumps</title></head><body><p><span>Overview</span></p><ul><li><p>TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements</p></li><li><p>Net loss for Q3 2025 increased due to higher R&amp;D expenses</p></li><li><p>Company reached FDA agreement on pivotal trial design for TSC-101</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash reserves to fund operations into the second half of 2027</p></li><li><p>Enrollment in solid tumor trial paused to focus on preclinical development</p></li></ul><p><span>Result Drivers</span></p><ul><li><p><span>R&amp;D EXPENSES: </span>Research and development (R&amp;D) expenses for the third quarter of 2025 were $31.7 million, compared to $26.3 million for the third quarter of 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration and License Revenue</p></td><td></td><td><p>$2.51 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$35.71 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.28</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$37.05 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$39.56 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 79.7% above its November 11 closing price of $1.22</p></li></ul><p>Press Release: <span>ID:nGNX9WGD6S</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TScan Therapeutics Q3 revenue jumps</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTScan Therapeutics Q3 revenue jumps\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>TScan <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 revenue jumps</title></head><body><p><span>Overview</span></p><ul><li><p>TScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreements</p></li><li><p>Net loss for Q3 2025 increased due to higher R&amp;D expenses</p></li><li><p>Company reached FDA agreement on pivotal trial design for TSC-101</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects cash reserves to fund operations into the second half of 2027</p></li><li><p>Enrollment in solid tumor trial paused to focus on preclinical development</p></li></ul><p><span>Result Drivers</span></p><ul><li><p><span>R&amp;D EXPENSES: </span>Research and development (R&amp;D) expenses for the third quarter of 2025 were $31.7 million, compared to $26.3 million for the third quarter of 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration and License Revenue</p></td><td></td><td><p>$2.51 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$35.71 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.28</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>-$37.05 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$39.56 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 79.7% above its November 11 closing price of $1.22</p></li></ul><p>Press Release: <span>ID:nGNX9WGD6S</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TCRX","symbol_name":"Tscan Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0D7:1","article_id":"2582375632","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582375632","pubTimestamp":1762949681,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TScan Therapeutics Q3 revenue jumpsOverviewTScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreementsNet loss for Q3 2025 increased due to higher R&D expensesCompany reached FDA agreem","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TCRX":"Tscan Therapeutics, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"TScan Therapeutics第三季度收入猛增","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TCRX":0.9},"content_text":"TScan Therapeutics Q3 revenue jumpsOverviewTScan Q3 2025 revenue rose to $2.5 mln, driven by collaboration agreementsNet loss for Q3 2025 increased due to higher R&D expensesCompany reached FDA agreement on pivotal trial design for TSC-101OutlookCompany expects cash reserves to fund operations into the second half of 2027Enrollment in solid tumor trial paused to focus on preclinical developmentResult DriversR&D EXPENSES: Research and development (R&D) expenses for the third quarter of 2025 were $31.7 million, compared to $26.3 million for the third quarter of 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Collaboration and License Revenue$2.51 mlnQ3 Net Income-$35.71 mlnQ3 Basic EPS-$0.28Q3 Income From Operations-$37.05 mlnQ3 Operating Expenses$39.56 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for TScan Therapeutics Inc is $6.00, about 79.7% above its November 11 closing price of $1.22Press Release: ID:nGNX9WGD6SFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}